FOSTER CITY, Calif. & ANN ARBOR, Mich.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilead and EVOQ will collaborate on preclinical development. Gilead has the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization. See press release here.
Recent Posts
- Join us on Wednesday, October 1st, 2025 for the 5th Annual Drug Discovery Symposium!
- Courage Therapeutics receives $7.8M investment to advance weight regulation drugs
- Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway
- A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance
- Tim Cernak sat down with Michigan Public radio show Stateside to discuss what role pharmacists can play in decreasing plant and animal extinctions.